S&P 500   4,353.29 (+0.08%)
DOW   34,300.19 (+0.39%)
QQQ   345.12 (+0.16%)
AAPL   161.11 (+0.89%)
MSFT   302.23 (+1.86%)
FB   298.87 (+1.44%)
GOOGL   2,615.90 (+1.21%)
AMZN   2,829.92 (+1.89%)
TSLA   860.49 (-8.21%)
NVDA   221.21 (-2.86%)
BABA   112.33 (-0.92%)
NIO   21.56 (-4.85%)
AMD   104.50 (-5.61%)
CGC   6.96 (-3.73%)
MU   80.36 (-1.96%)
GE   89.06 (-0.29%)
T   24.17 (-0.33%)
F   19.81 (-0.50%)
DIS   136.18 (+1.93%)
AMC   14.94 (-6.27%)
PFE   54.13 (+2.11%)
ACB   3.87 (-4.68%)
BA   192.21 (-1.06%)
S&P 500   4,353.29 (+0.08%)
DOW   34,300.19 (+0.39%)
QQQ   345.12 (+0.16%)
AAPL   161.11 (+0.89%)
MSFT   302.23 (+1.86%)
FB   298.87 (+1.44%)
GOOGL   2,615.90 (+1.21%)
AMZN   2,829.92 (+1.89%)
TSLA   860.49 (-8.21%)
NVDA   221.21 (-2.86%)
BABA   112.33 (-0.92%)
NIO   21.56 (-4.85%)
AMD   104.50 (-5.61%)
CGC   6.96 (-3.73%)
MU   80.36 (-1.96%)
GE   89.06 (-0.29%)
T   24.17 (-0.33%)
F   19.81 (-0.50%)
DIS   136.18 (+1.93%)
AMC   14.94 (-6.27%)
PFE   54.13 (+2.11%)
ACB   3.87 (-4.68%)
BA   192.21 (-1.06%)
S&P 500   4,353.29 (+0.08%)
DOW   34,300.19 (+0.39%)
QQQ   345.12 (+0.16%)
AAPL   161.11 (+0.89%)
MSFT   302.23 (+1.86%)
FB   298.87 (+1.44%)
GOOGL   2,615.90 (+1.21%)
AMZN   2,829.92 (+1.89%)
TSLA   860.49 (-8.21%)
NVDA   221.21 (-2.86%)
BABA   112.33 (-0.92%)
NIO   21.56 (-4.85%)
AMD   104.50 (-5.61%)
CGC   6.96 (-3.73%)
MU   80.36 (-1.96%)
GE   89.06 (-0.29%)
T   24.17 (-0.33%)
F   19.81 (-0.50%)
DIS   136.18 (+1.93%)
AMC   14.94 (-6.27%)
PFE   54.13 (+2.11%)
ACB   3.87 (-4.68%)
BA   192.21 (-1.06%)
S&P 500   4,353.29 (+0.08%)
DOW   34,300.19 (+0.39%)
QQQ   345.12 (+0.16%)
AAPL   161.11 (+0.89%)
MSFT   302.23 (+1.86%)
FB   298.87 (+1.44%)
GOOGL   2,615.90 (+1.21%)
AMZN   2,829.92 (+1.89%)
TSLA   860.49 (-8.21%)
NVDA   221.21 (-2.86%)
BABA   112.33 (-0.92%)
NIO   21.56 (-4.85%)
AMD   104.50 (-5.61%)
CGC   6.96 (-3.73%)
MU   80.36 (-1.96%)
GE   89.06 (-0.29%)
T   24.17 (-0.33%)
F   19.81 (-0.50%)
DIS   136.18 (+1.93%)
AMC   14.94 (-6.27%)
PFE   54.13 (+2.11%)
ACB   3.87 (-4.68%)
BA   192.21 (-1.06%)
NASDAQ:EGRX

Eagle Pharmaceuticals Stock Forecast, Price & News

$44.56
-0.85 (-1.87%)
(As of 01/27/2022 12:27 PM ET)
Add
Compare
Today's Range
$44.55
$45.63
50-Day Range
$45.41
$55.42
52-Week Range
$36.48
$58.25
Volume
270 shs
Average Volume
113,441 shs
Market Capitalization
$575.45 million
P/E Ratio
108.68
Dividend Yield
N/A
Beta
0.64
30 days | 90 days | 365 days | Advanced Chart
Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eagle Pharmaceuticals logo

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Headlines

Eagle Unveils Commercial Availability Of Vasopressin
January 18, 2022 |  markets.businessinsider.com
4 High Earnings Yield Stocks Likely to Pay Off Big Time
December 23, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EGRX
Fax
N/A
Employees
106
Year Founded
N/A

Sales & Book Value

Annual Sales
$187.80 million
Cash Flow
$1.27 per share
Book Value
$14.27 per share

Profitability

Net Income
$11.99 million
Pretax Margin
3.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
10,034,000
Market Cap
$575.45 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/27/2022
Next Earnings (Estimated)
3/01/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

164th out of 1,420 stocks

Pharmaceutical Preparations Industry

65th out of 684 stocks

Analyst Opinion: 2.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals
or view top-rated stocks.

How has Eagle Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EGRX stock has increased by 14.1% and is now trading at $44.56.
View which stocks have been most impacted by COVID-19
.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Eagle Pharmaceuticals
.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) posted its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to analyst estimates of $46.70 million. Eagle Pharmaceuticals had a net margin of 3.14% and a trailing twelve-month return on equity of 2.97%. During the same period in the prior year, the business posted $0.51 earnings per share.
View Eagle Pharmaceuticals' earnings history
.

What price target have analysts set for EGRX?

2 brokers have issued 12-month price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $51.00 to $51.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Scott L. Tarriff, President, Chief Executive Officer & Director
  • Michael Moran, Executive VP, Chief Operating & Commercial Officer
  • Brian Cahill, Chief Financial Officer
  • Daniel O'Connor, Chief Strategy Officer
  • David M. Pernock, Executive Vice President-Operations

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Smith Graham & Co. Investment Advisors LP (1.83%), Scout Investments Inc. (1.31%), Foundry Partners LLC (0.48%), Russell Investments Group Ltd. (0.10%), State of Alaska Department of Revenue (0.06%) and Cutler Group LP (0.01%).
View institutional ownership trends for Eagle Pharmaceuticals
.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Smith Graham & Co. Investment Advisors LP, Russell Investments Group Ltd., Scout Investments Inc., Foundry Partners LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Eagle Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Eagle Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $44.56.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $575.45 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at [email protected].


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.